Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia

American Journal of Hematology

Volumn 85, Issue 8, 2010, Pages 569-574

  Shearer, Brandon M ^a   Sukov, William R ^a   Flynn, Heather C ^a   Knudson, Ryan A ^a   Ketterling, Rhett P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CANCER DIAGNOSIS; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; EVI1 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RPN1 GENE; TUMOR GENE; ADOLESCENT; BACTERIAL ARTIFICIAL CHROMOSOME; BONE MARROW CELL; CHROMOSOME 3; CHROMOSOME INVERSION; CLINICAL TRIAL; DNA PROBE; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; METHODOLOGY; MIDDLE AGED; SINGLE BLIND PROCEDURE; ULTRASTRUCTURE; VALIDATION STUDY;

ONCOPROTEIN; RPN1 EVI1 FUSION PROTEIN, HUMAN; RPN1-EVI1 FUSION PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; BONE MARROW CELLS; CHROMOSOME INVERSION; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 3; DNA PROBES; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; MYELODYSPLASTIC SYNDROMES; ONCOGENE PROTEINS, FUSION; SINGLE-BLIND METHOD; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 77955502374     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21746     Document Type: Article

References (33)

1. Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. Blood 1985;66:1362-1370.
2. Fonatsch C, Gudat H, Lengfelder E, et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994;8:1318-1326.
3. Jenkins RB, Tefferi A, Solberg LA Jr, Dewald GW. Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. Cancer Genet Cytogenet 1989;39:167-179.
4. Jotterand Bellomo M, Parlier V, Muhlematter D, Grob JP, Beris P. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet 1992;59:138-160.
5. Rubin CM, Larson RA, Anastasi J, et al. t(3;21)(q26;q22): A recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 1990;76:2594-2598.
6. Stevens-Kroef M, Poppe B, van Zelderen-Bhola S, et al. Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. Leukemia 2004;18:1108-1114.
7. Shimizu S, Suzukawa K, Kodera T, et al. Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21). Genes Chromosomes Cancer 2000;27:229-238.
8. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia. 1997;11:2022-2031.
9. Poppe B, Dastugue N, Vandesompele J, et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer 2006;45:349-356.
10. Levy ER, Parganas E, Morishita K, et al. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. Blood 1994;83:1348-1354.
11. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 1996;93:1642-1647.
12. Kurokawa M, Mitani K, Irie K, et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998;394:92-96.
13. Sitailo S, Sood R, Barton K, Nucifora G. Forced expression of the leukemia-associated gene EVI1 in ES cells: A model for myeloid leukemia with 3q26 rearrangements. Leukemia 1999;13:1639-1645.
14. Morishita K, Parganas E, William CL, et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992;89:3937-3941.
15. Suzukawa K, Parganas E, Gajjar A, et al. Identification of a breakpoint cluster region 30 of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994;84:2681-2688.
16. Pekarsky Y, Zabarovsky E, Kashuba V, et al. Cloning of breakpoints in 3q21 associated with hematologic malignancy. Cancer Genet Cytogenet 1995;80:1-8.
17. Rynditch A, Pekarsky Y, Schnittger S, Gardiner K. Leukemia breakpoint region in 3q21 is gene rich. Gene 1997;193:49-57.
18. Wieser R, Volz A, Schnittger S, et al. Mapping of leukaemia-associated breakpoints in chromosome band 3q21 using a newly established PAC contig. Brit J Haematol 2000;110:343-350.
19. Pekarsky Y, Rynditch A, Wieser R, Fonatsch C, Gardiner K. Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia. Cancer Res 1997;57:3914-3919.
20. Martinelli G, Ottaviani E, Buonamici S, et al. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts. Haematologica 2003;88:1221-1228.
21. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and over-all survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.
22. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A southwest oncology group/eastern cooperative oncology group study. Blood 2000;96:4075-4083.
23. Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: A United Kingdom cancer cytogenetic group study. Brit J Haematol 1995;91:490-501.
24. Reiter E, Greinix H, Rabitsch W, et al. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol 2000;79:374-377.
25. Arber DA, BRD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SH, CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization Classification of Tumours. IARC Press: Lyon; 2008. pp 351.
26. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-3096.
27. Brockman SR, Paternoster SF, Ketterling RP, Dewald GW. New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. Cancer Genet Cytogenet 2003;145:144-151.
28. Testoni N, Borsaru G, Martinelli G, et al. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. Haematologica 1999;84:690-694.
29. Wieser R, Schreiner U, Pirc-Danoewinata H, et al. Interphase fluorescence in situ hybridization assay for the detection of 3q21 rearrangements in myeloid malignancies. Genes Chromosomes Cancer 2001;32:373-380.
30. Wiktor AE, Van Dyke DL, Stupca PJ, et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med 2006;8:16-23.
31. Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998;91:3357-3365.
32. Lahortiga I, Vazquez I, Agirre X, et al. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer 2004;40:179-189.
33. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003;101:837-845.